23andMe to offer direct-to-consumer pharmacogenetics reports

23andMe to offer direct-to-consumer pharmacogenetics reports

https://www.drugstorenews.com/pharmacy/23andme-to-offer-direct-to-consumer-pharmacogenetics-reports/

The Food and Drug Administration has granted consumer genetics and research company 23andMe de novo authorization to offer reports on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications.

This is the first authorization of a direct-to-consumer report on pharmacogenetics and came through the FDA’s de novo classification process. The FDA has classified these direct-to-consumer pharmacogenetic reports as moderate risk that have special controls to ensure safety, effectiveness and accuracy. This authorization enables 23andMe to report on numerous variants associated with pharmacogenetic response.

“We’ve continued to innovate through the FDA and pioneer safe, effective pathways for consumers to directly access genetic health information,” 23andMe co-founder and CEO Anne Wojcicki said in a statement. “Pharmacogenetic reports are an important category of information for consumers to get access to and I believe this authorization opens the door for consumers to work with their health providers to better manage their medications.”

23andMe had to demonstrate the accuracy of its testing and consumer comprehension of the testing information, including “treatment adherence” and whether or not a customer would continue their prescribed treatment of a medication, or change or stop treatment. Studies showed that more than 97% of users understood that they should not use the report to make any changes to treatment without consulting their doctor, the company said.

The authorization allows for the reporting of variants in multiple genes that impact how well an individual metabolizes certain medications, for example clopidogrel, which is commonly prescribed to prevent heart attacks and strokes. These genes are associated with response to more than 50 other commonly prescribed and over-the-counter medications. The authorization allows 23andMe to provide customers with information on whether they are predicted to be fast or slow metabolizers based on their genetics, and when supported by appropriate clinical evidence, whether they may experience reduced efficacy or have an increased chance of side effects from certain medications.

Finally, the company said that the decision continues the commitment made by 23andMe to return all the types of genetic health information to customers that it offered prior to an FDA warning letter in 2013. However, 23andMe has not determined when it will be able to make these new reports available to its customers.

One Response

  1. They already have Nonconsentualy, and without informed consent “ALTEREd”, Misrepresented, Lied to the majority of us w/o any concern what so ever for injury, death, and further .Disability. The “Rights” of the elderly, and people on disability were in fact violated under the former administration, and I haven’t been able to get ANY Lawyer, “Representative” or Anyone who is willing to help. Ifs clear that there is a covert take over of the American Constitution, and that after 911 the American Constitution was/is suspended. Congress was supposed to meet every 6 most after but only met once. Horizon 2030, Agenda 21 has quietly Rolled it’s way throughout the US. I know of no one who voted for this. GMO Frankenmeds without Transparency, Acountability, and consent. I’m literally Sick from this LAB RAT human rights Abuses. We Are Transparent, They Are InvisabIe. Thanks to corruption and war Technology used on whoever they choose to TARGET.

Leave a Reply

Discover more from PHARMACIST STEVE

Subscribe now to keep reading and get access to the full archive.

Continue reading